<DOC>
	<DOCNO>NCT00006093</DOCNO>
	<brief_summary>RATIONALE : EMD 121974 may stop growth cancer stop blood flow tumor . PURPOSE : Phase I/II trial study effectiveness EMD 121974 treat patient progressive recurrent malignant glioma .</brief_summary>
	<brief_title>EMD 121974 Treating Patients With Progressive Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity EMD 121974 patient progressive recurrent malignant glioma . - Determine 6-month progression-free survival , clinical response rate , duration progression-free survival , overall survival patient treated drug . - Determine effect drug tumor perfusion , measure magnetic resonance perfusion scan , marker angiogenesis patient . OUTLINE : This dose-escalation , multicenter study . Patients receive EMD 121974 IV 1 hour twice weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 6-12 patient receive escalate dos EMD 121974 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 4 12 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat MTD . Patients follow every 2 month . PROJECTED ACCRUAL : A minimum 6 patient accrued phase I study within 2-3 month . A total 23-38 patient accrue phase II study within 5-10 month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma progressive recurrent radiotherapy and/or chemotherapy Eligible subtypes : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Prior lowgrade glioma progress highgrade glioma ( biopsy ) radiotherapy and/or chemotherapy allow Measurable disease volumetric magnetic resonance perfusion scan Prior biopsy resection recurrent brain tumor allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal Transaminases great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No advanced coronary artery disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection medical illness would preclude study No malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer No history wound heal disorder No peptic ulcer disease within past year Mini mental score least 15 Willing able undergo MRI PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover No 2 prior chemotherapy regimen Endocrine therapy : Prior corticosteroid allow stable dose least 5 day prior study Concurrent corticosteroid ( e.g. , dexamethasone ) allow clinically need Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy recover Surgery : See Disease Characteristics At least 1 week since prior surgery recover No concurrent elective surgery dental extraction Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>